Navigation Links
Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
Date:6/13/2012

SAN DIEGO, June 13, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), (Nasdaq: TROVU),a developer of trans-renal molecular diagnostics, announced the full exercise of the over-allotment option granted to the underwriters to purchase 172,500 additional units, at a public offering price of $8.00 per unit, in connection with its previously announced underwritten public offering of 1,150,000 units, bringing total gross proceeds from the offering to $10,580,000.

On June 14, 2012, the holders of the Company's units may elect to separately trade the common stock and warrants underlying the units on The NASDAQ Capital Market under the symbols "TROV" and "TROVW", respectively. The warrants will be exercisable at an exercise price of $5.32 per share upon separation of the units and will expire on June 4, 2017. Those units not separated will continue to trade on The NASDAQ Capital Market under the symbol "TROVU". 

Aegis Capital Corp. acted as the sole book-running manager for the offering.

Summer Street Research Partners and Brean Murray, Carret & Co. acted as co-managers for the offering.

A registration statement on Form S-1 relating to the shares was filed with the Securities and Exchange Commission and is effective.  Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website. 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Trovagene, Inc.<
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 Demanding industrial ... Lenses engineered of synthetic Sapphire and Glass Ball Lenses, ... from Swiss Jewel Company , of Philadelphia , ... expanding and collimating the light beams without the need ... clarity and natural durability (9 mohs) make it the ...
(Date:6/18/2013)... 18, 2013 The Pistoia ... the HELM biomolecular representation standard software toolkit and ... HELM (Hierarchical Editing Language for Macromolecules) ... biomolecules (e.g. proteins, nucleotides, antibody drug conjugates) whose ... informatics methodologies impractical or unusable. HELM solves this ...
(Date:6/18/2013)... June 18, 2013 Mapi Pharma Ltd. ... and innovative intermediates, and finished dosage forms based on selected ... granted a United States patent for ... Europe for the oral treatment of moderate-to-severe acute ... Intermediate Compounds and Processes for the Preparation of Tapentadol ...
(Date:6/18/2013)... Texas , June 18, 2013   ... ), a biopharmaceutical company focused on discovering breakthrough ... John Northcott has joined the company as ... operations. Mr. Northcott brings extensive commercial experience to ... across a variety of therapeutic areas. ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... ULURU Inc. (NYSE Amex: ... the treatment of wounds using Altrazeal(TM) along with pre-clinical and ... at the annual Society for Advance Wound Care Conference ("SAWC") ... clinical evidence and data will be presented on posters on ...
... (Nasdaq: ANDS ), a biopharmaceutical company dedicated ... the areas of hepatitis C and oncology, today reported ... ended March 31, 2009. "We have now concluded three ... HCV patients that demonstrated potent antiviral activity over three ...
... N.J., April 23 Wyeth (NYSE: WYE ... of its outstanding $2 Convertible Preferred Stock, par value ... July 15, 2009 (the "Redemption Date"). As of ... Preferred Stock outstanding.The redemption price for each share of ...
Cached Biology Technology:ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009 2Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 8Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 9Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 10Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5
(Date:6/17/2013)... in Biochemical and Biophysical Research Communications , Saint ... new, previously unknown viruses. The technique offers the potential ... not identified a particular virus as the likely source ... approach, scientists use blood serum as a biological source ... the complete deciphering of the human genome, SLU researchers ...
(Date:6/17/2013)... MANHATTAN, KAN. -- A Kansas State University research associate ... on mosquitoes and ways to prevent the spread of ... received the National Institutes of Health,s National Research Service ... years. He is the seventh Kansas State University researcher ... on campus to currently hold such an award. , ...
(Date:6/17/2013)... . A new ... disease can be reversed with treatment. The study by researchers ... at McGill University and at Universit de Montral found that ... of mice with advanced Alzheimer,s disease (AD) recovers memory and ... Neuroinflammation in May, also suggest an underlying mechanism of ...
Breaking Biology News(10 mins):Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3NIH fellowship helps researcher fight malaria, understand mosquito immunity 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... RNA, a tiny chemical cousin of DNA, to turn on ... a gene awake would help alleviate disease, researchers at UT ... is being developed by UT Southwestern scientists, also is providing ... that genes play in human health. , In ...
... biology, known as ‘evo-devo? is being held back because ... to illustrate key questions about evolution, argue biologists in ... subject of evo-devo, which became established almost a decade ... organisms that have been inherited from developmental biology (fruit ...
... adult mice a drug - a synthetic designed to mimic ... now able to chemically switch on PPAR-d, the master regulator ... Even when the mice are not active, turning on the ... exercise. The resulting shift in energy balance (calories in, calories ...
Cached Biology News:Novel laboratory technique nudges genes into activity 2Novel laboratory technique nudges genes into activity 3Biologists call for better choice of model organisms in 'evo-devo' 2Biologists call for better choice of model organisms in 'evo-devo' 3'Exercise pill' switches on gene that tells cells to burn fat 2
... DH-2000, except that it uses a deep-UV deuterium ... and comes with a shutter (controlled via a ... The DH-2000 Deuterium Tungsten Halogen Light ... tungsten halogen light sources in a single optical ...
... Quidel's depleted sera are specifically depleted of ... of the depleted protein, the alternative and ... are therefore ideal for the detection and ... sera have been used to assess complement ...
... Identical to the D-2000, except that it uses ... nm wavelength range and comes with a shutter ... The D-2000 Deuterium Light Source produces a ... deep-UV versions of the light source are available, ...
... is a fully automated microplate based ... labs in academia and industry. The ... Fluorescence Intensity including FRET ... including DELFIATM High-Performance Luminescence ...
Biology Products: